Bispecific Toxicity Management in DLBCL Care


Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari interviews Mancini, discussing significant advancements and risk management associated with bispecific therapies in DLBCL. Mancini breaks down the 2 distinct phases of toxicity management: early phase, focusing on cytokine release syndrome (CRS), neurotoxicity, and tumor flares; and maintenance phase, addressing infection risks.

Mancini emphasizes the importance of following chimeric antigen receptor T-cell therapy guidelines for CRS and neurotoxicity management during the early phase, with corticosteroids as a go-to recommendation. He challenges the necessity of tocilizumab up front, asserting its potential additional costs and logistical challenges. In the maintenance phase, infection risks become a primary concern, highlighting T cell exhaustion and hypogammaglobulinemia. Prophylaxis measures, including antiviral and pneumocystis pneumonia prophylaxis, are crucial. Mancini addresses the hesitancy of some centers in providing maintenance due to past adverse effects but stresses the importance of infection prevention as a standard in oncology. The discussion underscores the need for comprehensive monitoring and proactive measures for long-term adverse effects in bispecific therapy.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.